Longeveron Q2 10-Q: Going Concern Doubt, Nasdaq Delisting Risk, Cash Runway to Q4
LGVN sits 44% above its 52-week low of $0.475 on elevated volume (2.4× avg).
Summary
Longeveron's Q2 10-Q reveals going concern doubt, a Nasdaq delisting risk, and a cash runway only into Q4 2026, alongside a net loss of $6.1 million for the quarter.
Updates
· Reuters — Q2 revenue down 10% year-over-year; gross profit rose 25% to $182,000; expects ELPIS II topline results in September 2026.
Key Events · Earnings and Guidance · LGVN
-
Going Concern Doubt
The company states there is substantial doubt about its ability to continue as a going concern, with cash of $10.1 million expected to fund operations only into Q4 2026.
-
Nasdaq Delisting Risk
Longeveron has until September 21, 2026 to regain compliance with Nasdaq's $1.00 minimum bid price requirement; failure could lead to delisting.
-
ATM Facility Restricted
The company cannot use its $10.7 million ATM facility unless the stock trades above $0.80 per share until September 7, 2026.
-
Q2 Net Loss Widens
Net loss for Q2 2026 was $6.1 million, up from $5.0 million in Q2 2025, driven by higher legal and personnel costs.
Analysis · LGVN · Life Sciences
Longeveron's Q2 2026 10-Q confirms the company has substantial doubt about its ability to continue as a going concern, with cash of $10.1 million expected to fund operations only into the fourth quarter of 2026. The company also faces a Nasdaq minimum bid price compliance deadline of September 21, 2026, and its ATM facility is restricted unless the stock trades above $0.80 until September 7, 2026. These disclosures materially raise the risk profile for shareholders, as the company must raise additional capital or regain compliance to avoid delisting and potential operational disruption.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGVN was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6M. The 52-week trading range was $0.48 to $1.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.